<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="ajrccm" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC4351578/" /><meta name="ncbi_app" content="pmc" />
        <!-- Logger end -->
        
        <title>Plasma Sphingolipids Associated with Chronic Obstructive Pulmonary
Disease Phenotypes</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351578/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="American Journal of Respiratory and Critical Care Medicine" /><meta name="citation_title" content="Plasma Sphingolipids Associated with Chronic Obstructive Pulmonary&#10;Disease Phenotypes" /><meta name="citation_authors" content="Russell P. Bowler, Sean Jacobson, Charmion Cruickshank, Grant J. Hughes, Charlotte Siska, Daniel S. Ory, Irina Petrache, Jean E. Schaffer, Nichole Reisdorph, Katerina Kechris" /><meta name="citation_date" content="1 February 2015" /><meta name="citation_issue" content="3" /><meta name="citation_volume" content="191" /><meta name="citation_firstpage" content="275" /><meta name="citation_doi" content="10.1164/rccm.201410-1771OC" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC4351578/?report=abstract" /><meta name="citation_pmid" content="25494452" /><meta name="DC.Title" content="Plasma Sphingolipids Associated with Chronic Obstructive Pulmonary&#10;Disease Phenotypes" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="American Thoracic Society" /><meta name="DC.Contributor" content="Russell P. Bowler" /><meta name="DC.Contributor" content="Sean Jacobson" /><meta name="DC.Contributor" content="Charmion Cruickshank" /><meta name="DC.Contributor" content="Grant J. Hughes" /><meta name="DC.Contributor" content="Charlotte Siska" /><meta name="DC.Contributor" content="Daniel S. Ory" /><meta name="DC.Contributor" content="Irina Petrache" /><meta name="DC.Contributor" content="Jean E. Schaffer" /><meta name="DC.Contributor" content="Nichole Reisdorph" /><meta name="DC.Contributor" content="Katerina Kechris" /><meta name="DC.Date" content="2015 Feb 1" /><meta name="DC.Identifier" content="10.1164/rccm.201410-1771OC" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Plasma Sphingolipids Associated with Chronic Obstructive Pulmonary&#10;Disease Phenotypes" /><meta property="og:type" content="article" /><meta property="og:description" content="Rationale: Chronic obstructive pulmonary disease (COPD) occurs in a&#10;minority of smokers and is characterized by intermittent exacerbations and clinical&#10;subphenotypes such as emphysema and chronic bronchitis. Although sphingolipids as a&#10;class are implicated ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351578/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.9.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.9.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'/pmc/utils/ctxp/'" /><script type="text/javascript" src="/corehtml/pmc/ctxp/jquery.citationexporter.js">//</script><link rel="stylesheet" href="/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-ajrccm.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC4351578/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC4351578/pdf/rccm.201410-1771OC.pdf" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="F4FB7B1CB4D247E100000000002D0020.m_8" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>
    <body class="article">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br />
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=%22Am J Respir Crit Care Med%22[journal]" class="navlink">Am J Respir Crit Care Med</a></li><li class="accid">PMC4351578</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-ajrccm.gif" alt="Logo of ajrccm" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="338,19,460,34" alt="Issue Featuring Article" title="Issue Featuring Article" href="http://ajrccm.atsjournals.org/content/vol191/issue3" ref="reftype=publisher&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext" /><area shape="rect" coords="338,3,494,18" alt="Publisher's Version of Article" title="Publisher's Version of Article" href="//dx.doi.org/10.1164/rccm.201410-1771OC" ref="reftype=publisher&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBanner&amp;TO=Content%20Provider%7CArticle%7CFullText&amp;rendering-type=normal" target="pmc_ext" /><area shape="rect" coords="338,36,411,49" alt="Submissions" title="Submissions" href="http://mc.manuscriptcentral.com/atsjournals" ref="reftype=publisher&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext" /><area shape="rect" coords="53,3,318,29" alt="American Thoracic Society" title="American Thoracic Society" href="http://www.thoracic.org/" ref="reftype=publisher&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext" /><area shape="rect" coords="1,1,52,55" alt="American Thoracic Society" title="American Thoracic Society" href="http://www.thoracic.org/" ref="reftype=publisher&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext" /><area shape="rect" coords="0,56,499,75" alt="American Journal of Respiratory and Critical Care Medicine" title="American Journal of Respiratory and Critical Care Medicine" href="http://ajrccm.atsjournals.org/" ref="reftype=publisher&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext" /></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">Am J Respir Crit Care Med</span>. 2015 Feb 1; 191(3): 275–284. </span></div><div><span class="fm-vol-iss-date">Published online 2015 Feb 1. </span>  <span class="doi">doi:  <a href="//dx.doi.org/10.1164%2Frccm.201410-1771OC" target="pmc_ext" ref="reftype=other&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1164/rccm.201410-1771OC</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC4351578</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/25494452">25494452</a></div></div></div></div></div><h1 class="content-title">Plasma Sphingolipids Associated with Chronic Obstructive Pulmonary
Disease Phenotypes</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Bowler%20RP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927595302048" co-class="co-affbox">Russell P. Bowler</a>,<sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>1</sup> <a href="/pubmed/?term=Jacobson%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927595376768" co-class="co-affbox">Sean Jacobson</a>,<sup>1</sup> <a href="/pubmed/?term=Cruickshank%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927668266992" co-class="co-affbox">Charmion Cruickshank</a>,<sup>1</sup> <a href="/pubmed/?term=Hughes%20GJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927595299696" co-class="co-affbox">Grant J. Hughes</a>,<sup>2</sup> <a href="/pubmed/?term=Siska%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927598804272" co-class="co-affbox">Charlotte Siska</a>,<sup>3</sup> <a href="/pubmed/?term=Ory%20DS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927598802160" co-class="co-affbox">Daniel S. Ory</a>,<sup>4,</sup><sup>5</sup> <a href="/pubmed/?term=Petrache%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927666489936" co-class="co-affbox">Irina Petrache</a>,<sup>6,</sup><sup>7</sup> <a href="/pubmed/?term=Schaffer%20JE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927599449008" co-class="co-affbox">Jean E. Schaffer</a>,<sup>4,</sup><sup>5</sup> <a href="/pubmed/?term=Reisdorph%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927594562704" co-class="co-affbox">Nichole Reisdorph</a>,<sup>1</sup> and  <a href="/pubmed/?term=Kechris%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452" class="affpopup" co-rid="_co_idm139927594560592" co-class="co-affbox">Katerina Kechris</a><sup>2</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139927595302048"><h3 class="no_margin">Russell P. Bowler</h3><p><sup>1</sup>National Jewish Health, Denver, Colorado</p><div>Find articles by <a href="/pubmed/?term=Bowler%20RP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Russell P. Bowler</a></div></div><div id="_co_idm139927595376768"><h3 class="no_margin">Sean Jacobson</h3><p><sup>1</sup>National Jewish Health, Denver, Colorado</p><div>Find articles by <a href="/pubmed/?term=Jacobson%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Sean Jacobson</a></div></div><div id="_co_idm139927668266992"><h3 class="no_margin">Charmion Cruickshank</h3><p><sup>1</sup>National Jewish Health, Denver, Colorado</p><div>Find articles by <a href="/pubmed/?term=Cruickshank%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Charmion Cruickshank</a></div></div><div id="_co_idm139927595299696"><h3 class="no_margin">Grant J. Hughes</h3><p><sup>2</sup>Department of Biostatistics and Informatics and</p><div>Find articles by <a href="/pubmed/?term=Hughes%20GJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Grant J. Hughes</a></div></div><div id="_co_idm139927598804272"><h3 class="no_margin">Charlotte Siska</h3><p><sup>3</sup>Computational Bioscience Program, University of Colorado Denver, Denver, Colorado</p><div>Find articles by <a href="/pubmed/?term=Siska%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Charlotte Siska</a></div></div><div id="_co_idm139927598802160"><h3 class="no_margin">Daniel S. Ory</h3><p><sup>4</sup>Diabetic Cardiovascular Disease Center and</p><p><sup>5</sup>Department of Medicine, Washington University, St. Louis, Missouri;</p><div>Find articles by <a href="/pubmed/?term=Ory%20DS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Daniel S. Ory</a></div></div><div id="_co_idm139927666489936"><h3 class="no_margin">Irina Petrache</h3><p><sup>6</sup>Indiana University School of Medicine, Indianapolis, Indiana; and</p><p><sup>7</sup>Richard L. Roudebush VA Medical Center, Indianapolis, Indiana</p><div>Find articles by <a href="/pubmed/?term=Petrache%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Irina Petrache</a></div></div><div id="_co_idm139927599449008"><h3 class="no_margin">Jean E. Schaffer</h3><p><sup>4</sup>Diabetic Cardiovascular Disease Center and</p><p><sup>5</sup>Department of Medicine, Washington University, St. Louis, Missouri;</p><div>Find articles by <a href="/pubmed/?term=Schaffer%20JE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Jean E. Schaffer</a></div></div><div id="_co_idm139927594562704"><h3 class="no_margin">Nichole Reisdorph</h3><p><sup>1</sup>National Jewish Health, Denver, Colorado</p><div>Find articles by <a href="/pubmed/?term=Reisdorph%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Nichole Reisdorph</a></div></div><div id="_co_idm139927594560592"><h3 class="no_margin">Katerina Kechris</h3><p><sup>2</sup>Department of Biostatistics and Informatics and</p><div>Find articles by <a href="/pubmed/?term=Kechris%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25494452">Katerina Kechris</a></div></div></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139927598339424_ai" style="display:none"><div class="fm-affl" lang="en" id="aff1"><sup>1</sup>National Jewish Health, Denver, Colorado</div><div class="fm-affl" lang="en" id="aff2"><sup>2</sup>Department of Biostatistics and Informatics and</div><div class="fm-affl" lang="en" id="aff3"><sup>3</sup>Computational Bioscience Program, University of Colorado Denver, Denver, Colorado</div><div class="fm-affl" lang="en" id="aff4"><sup>4</sup>Diabetic Cardiovascular Disease Center and</div><div class="fm-affl" lang="en" id="aff5"><sup>5</sup>Department of Medicine, Washington University, St. Louis, Missouri;</div><div class="fm-affl" lang="en" id="aff6"><sup>6</sup>Indiana University School of Medicine, Indianapolis, Indiana; and</div><div class="fm-affl" lang="en" id="aff7"><sup>7</sup>Richard L. Roudebush VA Medical Center, Indianapolis, Indiana</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div id="idm139927596036848">Correspondence and requests for reprints should be addressed to Russell Bowler, M.D., Ph.D., 1400 Jackson Street, Room K715a, Denver, CO 80206. E-mail: <a href="mailto:dev@null" data-email="gro.htlaehjn@rrelwob" class="oemail">gro.htlaehjn@rrelwob</a>; or Irina Petrache, M.D., 980 West Walnut Street, Walther Hall&#x02013;R3, C400, Indianapolis, IN 46260. E-mail: <a href="mailto:dev@null" data-email="ude.ui@hcartepi" class="oemail">ude.ui@hcartepi</a></div></div><div class="togglers"><a href="#" class="pmctoggle" rid="idm139927598339424_ai">Author information <span>►</span></a> <a href="#" class="pmctoggle" rid="idm139927598339424_an">Article notes <span>►</span></a> <a href="#" class="pmctoggle" rid="idm139927598339424_cpl">Copyright and License information <span>►</span></a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139927598339424_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2014 Oct 2; Accepted 2014 Dec 8.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="idm139927598339424_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2015 by the American Thoracic
Society</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="small"><div>See editorial "<a href="/pmc/articles/PMC4351583/">Bioactive Lipids in Emphysema. Decoding Fat to Reveal COPD
Phenotypes</a>" in volume 191 on page 241.</div><div style="border-top: 1px solid rgb(102, 102, 153); margin: 5px 10% 3px;"></div><div>This article has been <a href="/pmc/articles/PMC4351578/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="idm139927667487360" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139927667487360title">Abstract</h2><!--article-meta--><div><p id="__p1" class="p p-first"><strong>Rationale:</strong> Chronic obstructive pulmonary disease (COPD) occurs in a
minority of smokers and is characterized by intermittent exacerbations and clinical
subphenotypes such as emphysema and chronic bronchitis. Although sphingolipids as a
class are implicated in the pathogenesis of COPD, the particular sphingolipid species
associated with COPD subphenotypes remain unknown.</p><p id="__p2"><strong>Objectives:</strong> To use mass spectrometry to determine which plasma
sphingolipids are associated with subphenotypes of COPD.</p><p id="__p3"><strong>Methods:</strong> One hundred twenty-nine current and former smokers from the
COPDGene cohort had 69 distinct sphingolipid species detected in plasma by targeted
mass spectrometry. Of these, 23 were also measured in 131 plasma samples (117
independent subjects) using an untargeted platform in an independent laboratory.
Regression analysis with adjustment for clinical covariates, correction for false
discovery rate, and metaanalysis were used to test associations between COPD
subphenotypes and sphingolipids. Peripheral blood mononuclear cells were used to test
associations between sphingolipid gene expression and plasma sphingolipids.</p><p id="__p4"><strong>Measurements and Main Results:</strong> Of the measured plasma sphingolipids,
five sphingomyelins were associated with emphysema; four trihexosylceramides and
three dihexosylceramides were associated with COPD exacerbations. Three sphingolipids
were strongly associated with sphingolipid gene expression, and 15 sphingolipid
gene/metabolite pairs were differentially regulated between COPD cases and control
subjects.</p><p id="__p5" class="p p-last"><strong>Conclusions:</strong> There is evidence of systemic dysregulation of sphingolipid
metabolism in patients with COPD. Subphenotyping suggests that sphingomyelins are
strongly associated with emphysema and glycosphingolipids are associated with COPD
exacerbations.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">ceramides, sphingomyelins, emphysema, metabolomics, genomics</span></div></div><div id="idm139927592445376" class="tsec sec headless whole_rhythm"><div class="boxed-text-box whole_rhythm hide-overflow"><div class="sec"><h3>At a Glance Commentary</h3><div class="sec"><h4>Scientific Knowledge on the Subject</h4><p id="__p6" class="p p-first-last">In preclinical studies, ceramides, the basic unit of sphingolipids, has been
linked to emphysema development. However, the complexity of the sphingolipid
metabolism generates multiple sphingolipid species with distinct biological
functions, and chronic obstructive pulmonary disease (COPD) is a common disease
with multiple phenotypes, including emphysema. Recent data suggest an association
between circulating and sputum levels of sphingolipids and COPD, but only two
classes have been studied (ceramides and sphingomyelin), and these findings have
been neither validated in larger cohorts nor studied in relationship with distinct
COPD phenotypes.</p></div><div class="sec"><h4>What This Study Adds to the Field</h4><p id="__p7" class="p p-first-last">This study investigates the associations of plasma sphingolipids with COPD
subtypes such as airflow obstruction, emphysema, chronic bronchitis, and frequent
exacerbations in a well-characterized cohort of current or former smokers. Our
findings add to previous studies reporting associations of sphingomyelin and
ceramides with airflow obstruction and emphysema. In addition, we identified novel
sphingolipids associated with COPD phenotypes such as frequent COPD exacerbations.
We showed that COPD subphenotypes are associated with dysregulated gene/metabolite
pathways for sphingolipids, adding further evidence to their role in the
pathogenesis of COPD.</p></div></div></div><p id="__p8" class="p p-first">Chronic obstructive pulmonary disease (COPD) is the third leading
cause of death in the United States (<a href="#bib1" rid="bib1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751179">1</a>). Although
smoking is the major risk factor for COPD, most smokers do not develop COPD, and those who
do have variable clinical phenotypes such as airflow obstruction, emphysema, chronic
bronchitis, and frequent COPD exacerbations (<a href="#bib2" rid="bib2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751161">2</a>).
There is little known about what predisposes certain smokers to develop a particular COPD
phenotype. Recently, there have been reports suggesting that alteration in sphingolipid
metabolism may be linked to disease susceptibility (<a href="#bib3" rid="bib3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751175">3</a>&#x02013;<a href="#bib6" rid="bib6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751181">6</a>), although large-scale human
studies of specific sphingolipids have been lacking.</p><p id="__p9">Sphingolipids contain a backbone of sphingoid bases and, depending on the O-linked R group,
are subclassified into sphingosines, sphingomyelins, ceramides, or glycosphingolipids. In
mammals, there are more than 100 species of sphingolipids and a multitude of enzymes that
regulate sphingolipid metabolism. Sphingolipids are found primarily in cell membranes, but
also in biofluids such as plasma. Having pleiotropic effects, specific sphingolipids have
been implicated in diverse biologic processes (<a href="#bib7" rid="bib7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751145">7</a>)
that include: cell death, proliferation, differentiation, autophagy, senescence, migration,
and efferocytosis.</p><p id="__p10">Sphingolipids have been implicated in several lung diseases, including COPD (<a href="#bib3" rid="bib3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751150">3</a>, <a href="#bib8" rid="bib8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751154">8</a>, <a href="#bib9" rid="bib9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751162">9</a>). The majority of sphingolipid lung research has
focused on ceramides, the central intermediate metabolites in the sphingolipid metabolism
and key proapoptotic signaling molecules, and on sphingosine-1-phosphate (S1P), a
downstream metabolite of ceramide and key prosurvival and immune regulator. Smokers (<a href="#bib10" rid="bib10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751174">10</a>) and patients with COPD (<a href="#bib11" rid="bib11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751159">11</a>) have increased ceramides in their lungs, and ceramides have been
implicated in tobacco smoke&#x02013;induced pulmonary vascular cell apoptosis (<a href="#bib12" rid="bib12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_638654617">12</a>) and clearance of apoptotic cells by alveolar
macrophages (<a href="#bib13" rid="bib13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751170">13</a>). S1P receptor 5 expression is
reduced the lungs of patients with COPD (<a href="#bib14" rid="bib14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751143">14</a>), and
S1P analogs inhibit emphysema development in animal models (<a href="#bib15" rid="bib15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_638654615">15</a>). Recently, in a small cohort, sphingolipids were found elevated
in the sputum in COPD (<a href="#bib6" rid="bib6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751178">6</a>).</p><p id="__p11" class="p">These findings suggest that sphingolipid metabolism is dysregulated by smoking and COPD and
that these derangements may be pathogenic and could serve as biomarkers (<a href="#bib10" rid="bib10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751152">10</a>). However, previous studies have been limited by
small sample sizes, limited clinical phenotyping, and limited focus on a particular
subclass of sphingolipids. To overcome these limitations and further investigate
sphingolipids for their association with clinical COPD phenotypes, such as emphysema,
chronic bronchitis, and frequent exacerbations, we used two mass spectrometry&#x02013;based
approaches to quantitate 69 plasma sphingolipids in more than 250 smokers with and without
COPD from the COPDGene study. Furthermore, we integrated plasma metabolomics analyses with
recently published microarray profiling of this cohort (<a href="#bib4" rid="bib4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751165">4</a>) to discover relationships that might elucidate mechanisms of sphingolipid
dysregulation in COPD.</p></div><div id="__sec4" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec4title">Methods</h2><div id="__sec5" class="sec sec-first"><h3>Study Population</h3><p id="__p12" class="p p-first">The institutional review boards of participating
institutions approved this study. All subjects were from the COPDGene cohort, which
is a National Institutes of Health&#x02013;sponsored multicentered study of the
genetic epidemiology of COPD (<a href="#bib16" rid="bib16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751157">16</a>). From this
cohort we selected a subset of 129 subjects (<a href="/pmc/articles/PMC4351578/table/tbl1/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table
1</span></a>) for targeted sphingolipid analysis to obtain a wide range of COPD
phenotypes (defined below). Additionally, 131 subjects who participated in a
microarray study of gene expression in peripheral blood mononuclear cells (GEO
accession number GSE 42057) (<a href="#bib4" rid="bib4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751167">4</a>) were selected
for untargeted sphingolipid analysis. Additional details are provided in the online
supplement.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="tbl1"><h3>Table 1.</h3><!--caption a7--><div class="caption"><p id="__p13">Characteristics of Subjects</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139927595759232" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Targeted Cohort
(<em>N</em>&#x02009;=&#x02009;<em>129</em>)</th><th align="center" rowspan="1" colspan="1">Untargeted Cohort
(<em>N</em>&#x02009;=&#x02009;<em>131</em>)</th><th align="center" rowspan="1" colspan="1"><em>P</em>
Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, yr</td><td align="center" rowspan="1" colspan="1">63
(58&#x02013;71)</td><td align="center" rowspan="1" colspan="1">64
(57&#x02013;70)</td><td align="center" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, % men</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smokers, %</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Pack-years</td><td align="center" rowspan="1" colspan="1">46
(34&#x02013;58)</td><td align="center" rowspan="1" colspan="1">42
(30&#x02013;64)</td><td align="center" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index</td><td align="center" rowspan="1" colspan="1">27
(24&#x02013;31)</td><td align="center" rowspan="1" colspan="1">27
(24&#x02013;32)</td><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV<sub>1</sub> %</td><td align="center" rowspan="1" colspan="1">64
(40&#x02013;92)</td><td align="center" rowspan="1" colspan="1">66
(42&#x02013;89)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC</td><td align="center" rowspan="1" colspan="1">0.56
(0.39&#x02013;0.72)</td><td align="center" rowspan="1" colspan="1">0.61
(0.44&#x02013;0.74)</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Emphysema, %</td><td align="center" rowspan="1" colspan="1">11.5&#x02009;&#x000b1;&#x02009;11.4</td><td align="center" rowspan="1" colspan="1">9.18&#x02009;&#x000b1;&#x02009;10.4</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic bronchitis,
%</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Exacerbations/yr,
moderate</td><td align="center" rowspan="1" colspan="1">0.7&#x02009;&#x000b1;&#x02009;1.3</td><td align="center" rowspan="1" colspan="1">0.6&#x02009;&#x000b1;&#x02009;1</td><td align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Exacerbations/yr,
severe</td><td align="center" rowspan="1" colspan="1">0.2&#x02009;&#x000b1;&#x02009;0.7</td><td align="center" rowspan="1" colspan="1">0.1&#x02009;&#x000b1;&#x02009;0.3</td><td align="center" rowspan="1" colspan="1">0.17</td></tr></tbody></table></div><div id="largeobj_idm139927595759232" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4351578/table/tbl1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="idm139927591079808"><p id="__p14" class="p p-first-last">Data are presented as median (interquartile range) or mean &#x000b1; SD.
Emphysema was defined as percent of lung attenuation voxels below
&#x02212;950 Hounsfield units; chronic bronchitis was defined by daily
productive cough for at least 3 months in the previous 2 consecutive years;
exacerbations were defined as moderate (treated with either antibiotics or
corticosteroids) or severe (leading to hospitalization) in the previous
year.</p></div></div></div></div><div id="__sec6" class="sec"><h3>Clinical Data Collection and Definitions of COPD Phenotypes</h3><p id="__p15" class="p p-first-last">Each subject was classified by four different clinical
phenotypes: airflow obstruction (COPD), chronic bronchitis, emphysema, and
exacerbations (<em>see</em> Table E1 in the online supplement). COPD was
defined using Global Initiative for Chronic Obstructive Lung Disease criteria (<a href="#bib17" rid="bib17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751148">17</a>). Emphysema was measured using quantitative
high-resolution computed tomography (HRCT) as described (<a href="#bib18" rid="bib18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751146">18</a>). Exacerbations were defined by acutely worse cough, sputum,
and dyspnea in those with and without COPD. Only moderate exacerbations (treated by
corticosteroids and/or antibiotics) or severe exacerbations (causing hospitalization)
were counted. Chronic bronchitis was defined as cough that produces sputum daily for
3 consecutive months for at least 2 consecutive years.</p></div><div id="__sec7" class="sec"><h3>Sphingolipid Measurements</h3><p id="__p16" class="p p-first-last">Sphingolipid measurements were performed independently in
two separate laboratories using two separate protocols (<em>see</em> online
supplement for more details). A targeted, quantitative, mass spectrometry panel
(Washington University) included 69 sphingolipids (Table E2). Sphingomyelins,
dihydrosphingomyelins, ceramides, and dihydroceramides were extracted using a
modified Bligh-Dyer extraction method, in the presence of internal standards.
Sphingoid bases, ceramide-1-phosphate, monohexosylsphingosine, monohexosylceramides,
dihexosylceramides, trihexosylceramides, monohydroxylated monohexosylceramides,
monohydroxylated dihexosylceramides, sulfatides, and gangliosides were extracted
after protein precipitation with methanol, followed by supernatant collection,
drying, and reconstituting with 1:1 methanol/water, in the presence of internal
standards. A second untargeted protocol (National Jewish Health) was performed as
detailed elsewhere (<a href="#bib19" rid="bib19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751158">19</a>).</p></div><div id="__sec8" class="sec sec-last"><h3>Statistical Analysis</h3><p id="__p17" class="p p-first">Differences in demographic characteristics of study subjects
were analyzed using a <em>t</em> test for continuous variables and a
Chi-square test for categorical variables. Regression modeling and covariates are
described further in the online supplement. Because the sphingolipid levels were
highly correlated within class (Figure E1), we also computed the first principal
component of each sphingolipid class (Tables E3 and E4) using prcomp function in
R.</p><p id="__p18" class="p p-last">Replication between the targeted and untargeted platforms was determined using the
Stouffer-Liptak <em>Z</em>-score method, which converts the
<em>P</em> values from the two studies to normal quantiles and averages
them to obtain a combined <em>P</em> value (<a href="#bib20" rid="bib20" class=" bibr popnode">20</a>, <a href="#bib21" rid="bib21" class=" bibr popnode">21</a>). Each of the 23
sphingolipids that overlapped between the two studies was tested, and consistency in
the direction of the effect on the phenotype was taken into account.</p></div></div><div id="__sec9" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec9title">Results</h2><div id="__sec10" class="sec sec-first"><h3>Study Subjects and Baseline Characteristics</h3><p id="__p19" class="p p-first-last">Demographics, physiology, quantitative HRCT measurements,
and patient-reported outcomes for each group are listed in <a href="/pmc/articles/PMC4351578/table/tbl1/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a> and Table E1. Except for slightly more subjects with
emphysema in the untargeted cohort, there were no statistically significant
differences in the baseline characteristics between the targeted and untargeted
cohorts.</p></div><div id="__sec11" class="sec"><h3>Targeted Identification of Plasma Sphingolipids</h3><p id="__p20" class="p p-first">Our previous results suggested that sphingolipids were
candidate biomarkers for COPD (<a href="#bib4" rid="bib4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751176">4</a>); we
therefore performed targeted measurement of multiple sphingolipid classes. These
included: sphingomyelins (SM d18:1), dihydrosphingomyelins (SM d18:0), ceramides (Cer
d18:1), dihydroceramides (Cer d18:0), sphingoid bases, ceramide-1-phosphate,
monohexosylsphingosine, monohexosylceramides, dihexosylceramides,
trihexosylceramides, monohydroxylated monohexosylceramides, monohydroxylated
dihexosylceramides, sulfatides, and gangliosides. After filtering out species that
exhibited no or very low peaks, overlapped with other peaks, exhibited multiple peaks
with retention times in close proximity, or had large coefficients of variance, 69
sphingolipid species were used for quantitative comparisons (Table E2). Multiple
sphingolipids were associated with clinical covariates such as age, sex, body mass
index (BMI), and current smoking (Table E3). Three sphingolipid species showed a
negative correlation with age (correlation test <em>P</em>
value&#x02009;&#x0003c;&#x02009;0.01), seven species showed a negative correlation with
BMI (correlation <em>P</em> value&#x02009;&#x0003c;&#x02009;0.01), and 32 species
showed higher levels in female subjects (<em>t</em> test <em>P</em>
value&#x02009;&#x0003c;&#x02009;0.01). Although not significant, select species showed
trends for alterations depending on current smoking status. Because of these
associations, we adjusted for covariates in all our models.</p><p id="__p21" class="p p-last">Because strong correlations were noted within classes of sphingolipids (Figure E1),
sphingolipid species were further grouped into 10 classes (Table E4), which further
revealed robust interclass collinearities. For instance, plasma sphingomyelins were
strongly correlated with ceramides (<em>P</em>&#x02009;&#x0003c;&#x02009;0.001),
and both sphingomyelins and ceramides were inversely correlated with S1P
(<em>P</em>&#x02009;&#x0003c;&#x02009;0.001). Because of the high intraclass
correlations for plasma sphingolipids, each class of sphingolipids was also
represented in analyses by the first principal component from the intraclass
principal component analysis.</p></div><div id="__sec12" class="sec"><h3>Plasma Sphingolipids Association with Different Phenotypes of COPD</h3><p id="__p22" class="p p-first">Patients with COPD exhibit heterogeneity in clinical
presentation, with different morbidities and prognoses for each phenotype; therefore,
we investigated if specific sphingolipids or sphingolipid classes are significantly
associated with individual phenotypes. The most statistically significant negative
(inverse) association between specific COPD phenotypes and sphingolipid classes was
for emphysema and sphingomyelins; the most statistically significant positive
(direct) association was between COPD exacerbations and trihexosylceramides (<a href="/pmc/articles/PMC4351578/figure/fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig1" rid-ob="ob-fig1" co-legend-rid="lgnd_fig1"><span>Figure 1</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="fig1" co-legend-rid="lgnd_fig1"><a href="/pmc/articles/PMC4351578/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139927591503904" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4351578_rccm.201410-1771OC_f1.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is rccm.201410-1771OC_f1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4351578/bin/rccm.201410-1771OC_f1.jpg" /></a></div><div id="largeobj_idm139927591503904" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4351578/figure/fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig1"><div><a class="figpopup" href="/pmc/articles/PMC4351578/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1">Figure 1.</a></div><!--caption a7--><div class="caption"><p id="__p23">Heat map showing sphingolipids associated with specific chronic obstructive
pulmonary disease (COPD) phenotypes. Each class was represented by the first
principle component. Emphysema was defined as percent of lung attenuation
voxels below &#x02212;950 Hounsfield units; chronic bronchitis was defined by
daily productive cough for at least 3 months in the previous 2 consecutive
years; exacerbations (severe) were the number of hospital admissions for a COPD
admission in the previous year. Each phenotype was modeled using regression
with covariates (age, sex, smoking status, body mass index, and airflow
obstruction [FEV<sub>1</sub>] where appropriate), detailed in the online
methods. The color legend shows shading based on the signed &#x02212;10 log of
the <em>P</em> value with negative (&#x02212;) associations shown in
<em>blue</em> and <em>green</em> and positive (+)
associations shown in <em>orange</em> and <em>red</em> for each
sphingolipid class. Non&#x02013;statistically significant associations are shown
in <em>yellow</em> and <em>light orange</em>.</p></div></div></div><div id="__sec13" class="sec"><p></p><h4 class="inline">Individual sphingolipids associated with emphysema </h4><p id="__p24" class="p p-first">We identified 26 sphingolipids that were significantly associated with emphysema
after adjustment for covariates, with 8 remaining significant after adjustment for
false discovery rate (FDR) (Table E5). The most highly represented group was that
of sphingomyelins (10 species associated with emphysema, including 5 after
adjustment for false discovery), all of which had negative associations with
emphysema. The three plasma sphingolipids most significantly associated with
emphysema were ceramide d18.1.N16.0
(<em>P</em>&#x02009;=&#x02009;0.0006), ganglioside GM3 d18.1.N16.0
(<em>P</em>&#x02009;=&#x02009;0.0004), and sphingomyelin d18.1.N16.0
(<em>P</em>&#x02009;=&#x02009;0.0009), all being inversely
associated with emphysema (<a href="/pmc/articles/PMC4351578/figure/fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig2" rid-ob="ob-fig2" co-legend-rid="lgnd_fig2"><span>Figure 2</span></a>),
followed by monohexosylceramide d18.1.N16.0
(<em>P</em>&#x02009;=&#x02009;0.002; Table E5). When stratified by
subjects with less severe airflow obstruction (i.e., milder COPD), the receiver
operating characteristic curves demonstrated that these top sphingolipids improved
the ability to diagnose moderate to severe emphysema beyond just clinical and
physiologic covariates (Table E6).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="fig2" co-legend-rid="lgnd_fig2"><a href="/pmc/articles/PMC4351578/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139927598368672" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is rccm.201410-1771OC_f2.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is rccm.201410-1771OC_f2.jpg" src="/pmc/articles/PMC4351578/bin/rccm.201410-1771OC_f2.jpg" /></div><div id="largeobj_idm139927598368672" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4351578/figure/fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig2"><div><a class="figpopup" href="/pmc/articles/PMC4351578/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2">Figure 2.</a></div><!--caption a7--><div class="caption"><p id="__p25">Plasma ceramides are inversely associated with emphysema severity. Ceramide
(d18:1/N16:0), sphingomyelin (d18:1/N24:1), and sphingomyelin (d18:1/N16:0)
are representative examples (false discovery rate&#x02009;&#x0003c;&#x02009;0.02
in Table E5). Shown are box plots of median, quartiles, and outliers. A
total of 33, 91, 97, and 100% of subjects with no, mild, moderate, or severe
emphysema, respectively, had airflow obstruction (post-bronchodilator
FEV<sub>1</sub>/FVC&#x02009;&#x0003c;&#x02009;0.7).</p></div></div></div></div><div id="__sec14" class="sec"><p></p><h4 class="inline">Individual sphingolipids associated with COPD exacerbations </h4><p id="__p26" class="p p-first">After adjustment for covariates and correction for FDR, we identified 11
sphingolipids that were associated with severe COPD exacerbations, including four
trihexosylceramides, three dihexosylceramides, sulfatide d18.1.N16.0, ganglioside
GD1.d18.1.N16.0, sphingomyelin SM.d18.1.N14.1, and S1P (Table E7). All
associations were positive except for S1P and SM.d18.1.N14.1, and the strongest
signal was the positive association of severe COPD exacerbations with plasma
trihexosylceramides d18.1.N18.0 (adjusted
<em>P</em>&#x02009;=&#x02009;1.6&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup>).
Most of these associations were also identified with COPD exacerbations of lesser
severity (Table E8). Receiver operating characteristic analysis demonstrates that
these sphingolipids improved the ability to diagnose severe exacerbations beyond
just clinical and physiologic covariates (Table E9). Interestingly, for less
severe exacerbations, only in subjects with less airflow obstruction,
Cer.d18.1.N18.0 showed enhanced association with exacerbations beyond just
clinical and physiologic covariates (<a href="/pmc/articles/PMC4351578/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Figure
3</span></a> and Table E10).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="fig3" co-legend-rid="lgnd_fig3"><a href="/pmc/articles/PMC4351578/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139927633874432" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4351578_rccm.201410-1771OC_f3.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is rccm.201410-1771OC_f3.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4351578/bin/rccm.201410-1771OC_f3.jpg" /></a></div><div id="largeobj_idm139927633874432" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4351578/figure/fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig3"><div><a class="figpopup" href="/pmc/articles/PMC4351578/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3">Figure 3.</a></div><!--caption a7--><div class="caption"><p id="__p27">Receiver operating characteristics (ROC) curve analysis and area under the
curve (AUC) for sphingolipids significantly associated with moderate chronic
obstructive pulmonary disease exacerbations. The first model uses only the
demographic and clinical covariates (Covariates only), including covariates
age, sex, smoking status, body mass index, and airflow obstruction
(FEV<sub>1</sub>). The second model includes the same covariates and adds
plasma levels of Cer.d18.1.N18.0, which was the sphingolipid that most
improved ROC.</p></div></div></div></div><div id="__sec15" class="sec sec-last"><p></p><h4 class="inline">Sphingolipids associated with other COPD phenotypes (airflow obstruction and
chronic bronchitis) </h4><p id="__p28" class="p p-first-last">There were no plasma sphingolipid species significantly associated with chronic
bronchitis (Table E11), FEV<sub>1</sub> (data not shown), FEV<sub>1</sub>/FVC
(Table E11), or bronchodilator responsiveness (data not shown) after correcting
for FDR; however, several metabolomic trends noted in these subgroups were used in
combination with genomic data for phenotype-metabolomic interpretations.</p></div></div><div id="__sec16" class="sec"><h3>Replication of Associations between COPD Phenotypes and Sphingolipids</h3><p id="__p29" class="p p-first">For replication, we used an independently generated
metabolomics dataset (detected via untargeted mass spectrometry using orthogonal
methods in an independent laboratory) from plasma of 131 subjects in COPDGene.
Between the two datasets, we identified 23 overlapping sphingolipids (8
sphingomyelins, 6 ceramides, 3 gangliosides, 2 sulfogalactosylceramides,
dihydroceramide, trihexosylceramide, S1P, and sphingosine). For overlapping
sphingolipids, we performed metaanalysis of the two datasets accounting for the
direction of association. Seven of 23 sphingolipids showed negative associations with
emphysema, of which five sphingomyelins (<a href="/pmc/articles/PMC4351578/table/tbl2/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table
2</span></a>) exhibited the strongest signal for replication between the two platforms
(FDR&#x02009;&#x0003c;&#x02009;0.10). Four sphingolipids demonstrated associations with
moderate and severe exacerbations (<a href="/pmc/articles/PMC4351578/table/tbl3/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>).
Except for S1P, all were positively associated with exacerbations
(FDR&#x02009;&#x0003c;&#x02009;0.10).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="tbl2"><h3>Table 2.</h3><!--caption a7--><div class="caption"><p id="__p30">Metaanalysis of Sphingolipids Associated with Emphysema</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139927600624880" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="2" align="left" colspan="1">Sphingolipid</th><th colspan="2" align="center" rowspan="1">Targeted Cohort<hr /></th><th colspan="2" align="center" rowspan="1">Untargeted Cohort<hr /></th><th rowspan="2" align="center" colspan="1">Metaanalysis
<em>P</em> Value</th></tr><tr><th align="center" rowspan="1" colspan="1"><math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="m1" overflow="scroll"><mrow><mover accent="true"><mi mathvariant="italic">&#x003b2;</mi><mo>^</mo></mover></mrow></math> Slope</th><th align="center" rowspan="1" colspan="1"><em>P</em>
Value</th><th align="center" rowspan="1" colspan="1"><math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="m2" overflow="scroll"><mrow><mover accent="true"><mi>&#x003b2;</mi><mo>^</mo></mover></mrow></math> Slope</th><th align="center" rowspan="1" colspan="1"><em>P</em>
Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ganglioside GM3
(d18:1/16:0)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.7654</td><td align="center" rowspan="1" colspan="1">0.0004</td><td align="center" rowspan="1" colspan="1">&#x02212;0.1277</td><td align="center" rowspan="1" colspan="1">0.3768</td><td align="center" rowspan="1" colspan="1">0.0018<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Sphingomyelin(d18:0/24:1(15Z))</td><td align="center" rowspan="1" colspan="1">&#x02212;0.4534</td><td align="center" rowspan="1" colspan="1">0.0057</td><td align="center" rowspan="1" colspan="1">&#x02212;0.0623</td><td align="center" rowspan="1" colspan="1">0.5349</td><td align="center" rowspan="1" colspan="1">0.0167<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Sphingomyelin(d18:1/14:0)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.4335</td><td align="center" rowspan="1" colspan="1">0.0040</td><td align="center" rowspan="1" colspan="1">&#x02212;0.1070</td><td align="center" rowspan="1" colspan="1">0.3650</td><td align="center" rowspan="1" colspan="1">0.0075<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Sphingomyelin(d18:1/16:0)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.8964</td><td align="center" rowspan="1" colspan="1">0.0010</td><td align="center" rowspan="1" colspan="1">&#x02212;0.1867</td><td align="center" rowspan="1" colspan="1">0.4258</td><td align="center" rowspan="1" colspan="1">0.0037<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Sphingomyelin(d18:1/16:1)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.5198</td><td align="center" rowspan="1" colspan="1">0.0054</td><td align="center" rowspan="1" colspan="1">&#x02212;0.1459</td><td align="center" rowspan="1" colspan="1">0.3621</td><td align="center" rowspan="1" colspan="1">0.0090<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Sphingomyelin(d18:1/24:1(15Z))</td><td align="center" rowspan="1" colspan="1">&#x02212;0.6062</td><td align="center" rowspan="1" colspan="1">0.0009</td><td align="center" rowspan="1" colspan="1">&#x02212;0.2182</td><td align="center" rowspan="1" colspan="1">0.0829</td><td align="center" rowspan="1" colspan="1">0.0004<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Sphingomyelin(d18:2/14:0)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.3520</td><td align="center" rowspan="1" colspan="1">0.0237</td><td align="center" rowspan="1" colspan="1">&#x02212;0.0673</td><td align="center" rowspan="1" colspan="1">0.5444</td><td align="center" rowspan="1" colspan="1">0.0425</td></tr></tbody></table></div><div id="largeobj_idm139927600624880" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4351578/table/tbl2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="tblfn1"><sup>*</sup>False discovery rate&#x02009;&#x0003c;&#x02009;0.10.</div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="tbl3"><h3>Table 3.</h3><!--caption a7--><div class="caption"><p id="__p32">Metaanalysis of Sphingolipids Associated with Exacerbations</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139927592449808" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="2" align="left" colspan="1">Sphingolipid</th><th colspan="2" align="center" rowspan="1">Targeted Cohort<hr /></th><th colspan="2" align="center" rowspan="1">Untargeted Cohort<hr /></th><th rowspan="2" align="center" colspan="1">Metaanalysis
<em>P</em> Value</th></tr><tr><th align="center" rowspan="1" colspan="1"><math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="m3" overflow="scroll"><mrow><mover accent="true"><mi>&#x003b2;</mi><mo>^</mo></mover></mrow></math> Slope</th><th align="center" rowspan="1" colspan="1"><em>P</em>
Value</th><th align="center" rowspan="1" colspan="1"><math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="m4" overflow="scroll"><mrow><mover accent="true"><mi>&#x003b2;</mi><mo>^</mo></mover></mrow></math> Slope</th><th align="center" rowspan="1" colspan="1"><em>P</em>
Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sphingosine
1-phosphate</td><td align="center" rowspan="1" colspan="1">&#x02212;0.7051</td><td align="center" rowspan="1" colspan="1">0.1838</td><td align="center" rowspan="1" colspan="1">&#x02212;0.6928</td><td align="center" rowspan="1" colspan="1">0.0004</td><td align="center" rowspan="1" colspan="1">0.0006<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Trihexosylceramide
(d18:1/16:0)</td><td align="center" rowspan="1" colspan="1">0.8804</td><td align="center" rowspan="1" colspan="1">0.0693</td><td align="center" rowspan="1" colspan="1">0.9839</td><td align="center" rowspan="1" colspan="1">0.0059</td><td align="center" rowspan="1" colspan="1">0.0012<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">3-O-Sulfogalactosylceramide
(d18:1/16:0)</td><td align="center" rowspan="1" colspan="1">0.8262</td><td align="center" rowspan="1" colspan="1">0.0507</td><td align="center" rowspan="1" colspan="1">0.5191</td><td align="center" rowspan="1" colspan="1">0.0792</td><td align="center" rowspan="1" colspan="1">0.0087<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Galabiosylceramide
(d18:1/24:1(15Z))</td><td align="center" rowspan="1" colspan="1">0.6077</td><td align="center" rowspan="1" colspan="1">0.1741</td><td align="center" rowspan="1" colspan="1">0.4177</td><td align="center" rowspan="1" colspan="1">0.0641</td><td align="center" rowspan="1" colspan="1">0.0232</td></tr></tbody></table></div><div id="largeobj_idm139927592449808" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4351578/table/tbl3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="tblfn2"><sup>*</sup>False discovery rate&#x02009;&#x0003c;&#x02009;0.10.</div></div></div></div><div id="__sec17" class="sec sec-last"><h3>Relationship between Plasma Sphingolipids and Gene Expression in Smokers with and
without COPD</h3><p id="__p34" class="p p-first">All subjects in the untargeted metabolomics dataset had
microarray data generated from peripheral blood mononuclear cells collected from the
same plasma analyzed for metabolomics. Thus, we were able to explore relationships
between plasma sphingolipid metabolites and potentially related sphingolipid pathway
genes (Table E13). The most significant correlations were between
<em>N</em>-(tetradecanoyl)-sphing-4-enine-1-(2-aminoethylphosphonate) and GM2
ganglioside activator (&#x003c1;&#x02009;=&#x02009;&#x02212;0.39;
<em>P</em>&#x02009;=&#x02009;0.00001; FDR&#x02009;=&#x02009;0.04),
between SM(d18:1/12:0) and lysosomal sialidase
(&#x003c1;&#x02009;=&#x02009;&#x02212;0.36;
<em>P</em>&#x02009;=&#x02009;0.00007; FDR&#x02009;=&#x02009;0.12)
(Figure E2), and between sphingosine and Ceroid-Lipofuscinosis, Neuronal 8
(&#x003c1;&#x02009;=&#x02009;&#x02212;0.34;
<em>P</em>&#x02009;=&#x02009;0.0002; FDR&#x02009;=&#x02009;0.03).</p><p id="__p35" class="p">After interrogation of correlations between sphingolipid metabolite and gene
expression and clinical phenotype, subjects who reported moderate or severe COPD
exacerbations were most likely to have discordant correlations for
gene&#x02013;metabolite pairs (<a href="/pmc/articles/PMC4351578/table/tbl4/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl4" rid-ob="ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). For
example, the gene&#x02013;metabolite pair C9orf47 and
NeuGc&#x003b1;2-8NeuGc&#x003b1;2-3Gal&#x003b2;1-4GlcNAc&#x003b2;1-3Gal&#x003b2;1-4Glc&#x003b2;-Cer(d18:1/24:1[15Z])
had correlations &#x02212;0.19 and 0.64 in subjects without or with severe COPD
exacerbations, respectively (<em>P</em>&#x02009;=&#x02009;0.00001;
FDR&#x02009;=&#x02009;0.01) (<a href="/pmc/articles/PMC4351578/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span>Figure 4</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="tbl4"><h3>Table 4.</h3><!--caption a7--><div class="caption"><p id="__p36">Differential Metabolite&#x02013;Gene Expression Correlations for Sphingolipids
by Chronic Obstructive Pulmonary Disease Phenotype</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139927594947200" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1">Sphingolipid</th><th align="center" rowspan="1" colspan="1">Gene</th><th align="center" rowspan="1" colspan="1">COPD
Subphenotype</th><th align="center" rowspan="1" colspan="1">&#x003c1; without
Phenotype</th><th align="center" rowspan="1" colspan="1">&#x003c1; with
Phenotype</th><th align="center" rowspan="1" colspan="1"><em>P</em>
Value</th><th align="center" rowspan="1" colspan="1">FDR</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><em>N</em>-(tetradecanoyl)-sphing-4-enine-1-(2-aminoethylphosphonate)<sup>*</sup></td><td align="left" rowspan="1" colspan="1"><em>KDSR</em></td><td rowspan="2" align="left" colspan="1">Moderate or severe
exacerbation</td><td align="center" rowspan="1" colspan="1">&#x02212;0.17</td><td align="center" rowspan="1" colspan="1">0.50</td><td align="center" rowspan="1" colspan="1">0.00005</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">SM(d18:1/16:1)</td><td align="left" rowspan="1" colspan="1"><em>GM2A</em></td><td align="center" rowspan="1" colspan="1">&#x02212;0.15</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">0.00001</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">CerP(d18:1/24:1(15Z))<sup>*</sup></td><td align="left" rowspan="1" colspan="1"><em>ST8SIA2</em></td><td rowspan="11" align="left" colspan="1">Severe
exacerbation</td><td align="center" rowspan="1" colspan="1">&#x02212;0.05</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">0.00006</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">NeuGc&#x003b1;2-3Gal&#x003b2;1-4GlcNAc&#x003b2;1-3Gal&#x003b2;1-4Glc&#x003b2;-Cer(d18:1/24:1(15Z))<sup>*</sup></td><td align="left" rowspan="1" colspan="1"><em>C9orf47</em></td><td align="center" rowspan="1" colspan="1">&#x02212;0.19</td><td align="center" rowspan="1" colspan="1">0.64</td><td align="center" rowspan="1" colspan="1">0.00001</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Cer d18:1 N16:0</td><td align="left" rowspan="1" colspan="1"><em>ACER3</em></td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">0.00001</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">*1-3Gal&#x003b1;1-3Gal&#x003b1;1-3Gal&#x003b1;1-4Gal&#x003b2;1-4Glc&#x003b2;-Cer(d18:1/24:1(15Z))<sup>*</sup></td><td align="left" rowspan="1" colspan="1"><em>C9orf47</em></td><td align="center" rowspan="1" colspan="1">&#x02212;0.23</td><td align="center" rowspan="1" colspan="1">0.56</td><td align="center" rowspan="1" colspan="1">0.00009</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Cer d18:1 N16:0</td><td align="left" rowspan="1" colspan="1"><em>VAPA</em></td><td align="center" rowspan="1" colspan="1">&#x02212;0.03</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">0.00014</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Cer(d18:1/24:1(15Z))<sup>*</sup></td><td align="left" rowspan="1" colspan="1"><em>COL4A3BP</em></td><td align="center" rowspan="1" colspan="1">&#x02212;0.07</td><td align="center" rowspan="1" colspan="1">0.60</td><td align="center" rowspan="1" colspan="1">0.00019</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Cer(d16:1/23:0)<sup>*</sup></td><td align="left" rowspan="1" colspan="1"><em>COL4A3BP</em></td><td align="center" rowspan="1" colspan="1">&#x02212;0.12</td><td align="center" rowspan="1" colspan="1">0.56</td><td align="center" rowspan="1" colspan="1">0.00040</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Cer d18:1 N16:0</td><td align="left" rowspan="1" colspan="1"><em>KDSR</em></td><td align="center" rowspan="1" colspan="1">&#x02212;0.10</td><td align="center" rowspan="1" colspan="1">0.55</td><td align="center" rowspan="1" colspan="1">0.00055</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Cer d18:1 N16:0</td><td align="left" rowspan="1" colspan="1"><em>ORMDL1</em></td><td align="center" rowspan="1" colspan="1">&#x02212;0.14</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">0.00051</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">SM(d18:0/24:1(15Z))<sup>*</sup></td><td align="left" rowspan="1" colspan="1"><em>CYR61</em></td><td align="center" rowspan="1" colspan="1">&#x02212;0.18</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">0.00048</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">First PC ceramides</td><td align="left" rowspan="1" colspan="1"><em>COL4A3BP</em></td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">0.00242</td><td align="center" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">First PC
sphingosines</td><td align="left" rowspan="1" colspan="1"><em>ST8SIA3</em></td><td align="left" rowspan="1" colspan="1">Emphysema (upper
lobe)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.47</td><td align="center" rowspan="1" colspan="1">0.19</td><td align="center" rowspan="1" colspan="1">0.00039</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">First PC
sphingosines</td><td align="left" rowspan="1" colspan="1"><em>CYR61</em></td><td align="left" rowspan="1" colspan="1">Airflow
obstruction</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">&#x02212;0.39</td><td align="center" rowspan="1" colspan="1">0.00011</td><td align="center" rowspan="1" colspan="1">0.02</td></tr></tbody></table></div><div id="largeobj_idm139927594947200" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4351578/table/tbl4/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="idm139927596434304"><p id="__p37" class="p p-first-last"><em>Definition of abbreviations</em>:
COPD&#x02009;=&#x02009;chronic obstructive pulmonary disease;
FDR&#x02009;=&#x02009;false discovery rate;
PC&#x02009;=&#x02009;principal component.</p></div><div id="tblfn3"><sup>*</sup>Discovered in the untargeted profiling.</div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="fig4" co-legend-rid="lgnd_fig4"><a href="/pmc/articles/PMC4351578/figure/fig4/" target="figure" rid-figpopup="fig4" rid-ob="ob-fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139927600980480" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4351578_rccm.201410-1771OC_f4.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is rccm.201410-1771OC_f4.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4351578/bin/rccm.201410-1771OC_f4.jpg" /></a></div><div id="largeobj_idm139927600980480" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4351578/figure/fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig4"><div><a class="figpopup" href="/pmc/articles/PMC4351578/figure/fig4/" target="figure" rid-figpopup="fig4" rid-ob="ob-fig4">Figure 4.</a></div><!--caption a7--><div class="caption"><p id="__p39">Disruption of sphingolipid metabolite&#x02013;gene correlations by chronic
obstructive pulmonary disease (COPD) phenotype. Scatterplot of
NeuGc&#x003b1;2-3Gal&#x003b2;1-4GlcNAc&#x003b2;1-3Gal&#x003b2;1-4Glc&#x003b2;-Cer(d18:1/24:1(15Z))
and C9orf47 gene expression. Subjects without severe COPD exacerbations had a
correlation of &#x02212;0.19, whereas subjects with a history of severe COPD
exacerbations had a correlation of 0.64
(<em>P</em>&#x02009;=&#x02009;0.00001; false discovery
rate&#x02009;=&#x02009;0.01).</p></div></div></div></div></div><div id="__sec18" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec18title">Discussion</h2><p id="__p40" class="p p-first">This study of more than 250 subjects from the COPDGene cohort
is the largest and the only combined targeted and nontargeted metabolomic study of
plasma sphingolipid species in smokers with and without COPD; it is the first to link
specific sphingolipids with distinct COPD phenotypes. We identified novel sphingolipid
subclasses such as gangliosides and sphingomyelins as potential biomarkers inversely
associated with severe emphysema and trihexosylceramide as a potential biomarker
positively associated with frequent COPD exacerbations. All these associations were
noted even after adjusting for covariates of age, smoking status, airflow obstruction,
sex, and BMI; most were replicated in an independent cohort using an orthogonal mass
spectrometry approach in a different laboratory.</p><p id="__p41">Sphingomyelins are integral components of the plasma membrane, typically enriched in
lipid microdomains of caveolae and clathrin-coated pits (<a href="#bib22" rid="bib22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751168">22</a>). Sphingomyelins are produced from ceramides via sphingomyelin
synthase, or they can generate ceramides through hydrolysis by sphingomyelinases (<a href="/pmc/articles/PMC4351578/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure 5</span></a>). In addition to rapidly generating
ceramides as second messengers, sphingomyelins may themselves play a role in cell
migration, apoptosis, autophagy, and cell survival/proliferation (<a href="#bib22" rid="bib22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751184">22</a>). We identified 10 specific sphingomyelins (e.g.,
SM.d18.1.N16.0) that were inversely associated with emphysema, whereas others (e.g.,
SM.d18.1.N18.0) were not. These species-specific effects could only be studied with mass
spectrometry; however, we also noted strong correlations among the whole subclass of
sphingomyelins. A recent report (<a href="#bib5" rid="bib5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751187">5</a>) found no
statistically significant association between HRCT-measured emphysema severity at
baseline and sphingomyelin, measured with less accurate spectrophotometric assays (<a href="#bib23" rid="bib23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751141">23</a>). However, low baseline plasma sphingomyelin
was associated with worse COPD (lower FEV<sub>1</sub>), whereas high levels were
associated with more rapid progression of emphysema. Our data support the finding that
worse COPD is associated with lower plasma sphingomyelins (<a href="#bib5" rid="bib5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751183">5</a>), but the apparent paradoxical observation of higher plasma
sphingomyelins with progression of emphysema cannot be validated by our experimental
design. Such observation might be explained if low sphingomyelin levels reflect low lung
mass and progression of emphysema occurs in lungs that are not yet severely
emphysematous. This could be explored by careful kinetics of specific sphingomyelins
accompanied by concomitant HRCT measurements of the lung.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="fig5" co-legend-rid="lgnd_fig5"><a href="/pmc/articles/PMC4351578/figure/fig5/" target="figure" rid-figpopup="fig5" rid-ob="ob-fig5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139927600528480" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is rccm.201410-1771OC_f5.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is rccm.201410-1771OC_f5.jpg" src="/pmc/articles/PMC4351578/bin/rccm.201410-1771OC_f5.jpg" /></div><div id="largeobj_idm139927600528480" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4351578/figure/fig5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig5"><div><a class="figpopup" href="/pmc/articles/PMC4351578/figure/fig5/" target="figure" rid-figpopup="fig5" rid-ob="ob-fig5">Figure 5.</a></div><!--caption a7--><div class="caption"><p id="__p42">Sphingolipids metabolo-genomic pathway patterns associated with chronic
obstructive pulmonary disease (COPD) subphenotypes. (<em>A</em>) Detailed
sphingolipid metabolic pathway with the major ceramide synthetic pathways noted as
sphingomyelinase, <em>de novo</em>, and recycling pathways (abbreviations
list in the text). Individual or classes of metabolites measured in the study are
identified as precursors and/or products relative to synthetic or catabolic
reactions with directionality marked by <em>black arrows</em>. Catalytic
enzymes are noted next to the middle of the reactions <em>arrow</em>.
<em>Circled</em> are enzymes whose genes were significantly related
with COPD phenotypes in genomic analyses. In color are classes
(<em>arrowheads</em>) or species (<em>arrows</em>) of
metabolites that were associated with respective (color-coded) COPD phenotypes.
<em>Solid arrows</em> indicate: 16&#x02013;18 carbon chain
sphingolipids; <em>dotted arrows</em> 24&#x02013;26 carbon chain
sphingolipids; <em>single dash arrows</em>: 14 carbon chain sphingolipids.
The direction of the <em>arrowhead</em> or <em>arrow</em> marks
the direction of association (i.e., up: increased; down: decreased).
<em>Closed-headed arrows</em> represent changes with significance
levels <em>P</em>&#x02009;&#x0003c;&#x02009;0.05. (<em>B</em>,
<em>C</em>) Superimposed on the sphingolipid metabolic pathways are
deducted directions of sphingolipid metabolic flux, based on the results of the
metabolo-genomic study, by disease phenotype, as noted.</p></div></div></div><p id="__p43">Plasma ceramides may be generated by activated plasma sphingomyelinases (<a href="#bib24" rid="bib24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751173">24</a>) (<a href="/pmc/articles/PMC4351578/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure
5</span></a>) and could signal outside-in (<a href="#bib25" rid="bib25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751142">25</a>)
and/or be further metabolized to sphingosine (by plasma ceramidases). To the extent that
plasma levels reflect cellular metabolism, the decrease in both sphingomyelins and
ceramides with subsequent increases in ceramide metabolites suggests that low
sphingomyelin levels are not due to a blockage in sphingomyelin synthase (which would
result in ceramide accumulation) but due to increased catabolism coupled with decreased
availability of its building block precursor, ceramide (<a href="/pmc/articles/PMC4351578/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure 5</span></a>). In such conditions, supplementation of sphingomyelin may fuel
ceramide production and catabolism, by a &#x0201c;revved up&#x0201d; system. Plasma
sphingomyelins might also reflect the burden or quality of circulating (shed) cellular
plasma membranes, such as apoptotic microparticles or exosomes. Clearly, these unbiased
metabolomic results raise important mechanistic questions that can be explored in models
of COPD.</p><p id="__p44">Ceramides (especially Cer.d18.1.N16.0), gangliosides (especially GM3.d18.1.N16.0), and
monohexosylceramides (especially monohexcer.d18.1.N16.0) also showed an inverse
correlation with emphysema. Although ceramides have been known to play a role in the
pathogenesis of emphysema for several years (<a href="#bib10" rid="bib10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751171">10</a>, <a href="#bib26" rid="bib26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_529616428">26</a>), the involvement of
gangliosides and monohexosylceramides has not been described. An up-regulation of
ceramide production has been typically associated with models of emphysema, by causing
endothelial and epithelial cell apoptosis (<a href="#bib3" rid="bib3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751163">3</a>) or
by inhibiting alveolar macrophage clearance of apoptotic cells (<a href="#bib13" rid="bib13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751144">13</a>). In this cross-sectional sampling, the inverse correlation of
plasma ceramides with emphysema appears surprising. However, if our global metabolomics
assessment of plasma sphingolipids reflects pulmonary cellular events, worse emphysema
may be linked to increased activity of both sphingomyelinase and recycling (from
gangliosides) pathways, followed by ceramide consumption/degradation, rather than
accumulation (<a href="/pmc/articles/PMC4351578/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure 5</span></a>), possibly via plasma
ceramidases. Because plasma S1P was not increased and tended to be negatively correlated
with emphysema and COPD exacerbations, unlike sphingosine, it is possible that the
sphingolipid metabolism is accelerated toward ceramide production and degradation but
inhibited at the level of sphingosine kinase activity (<a href="/pmc/articles/PMC4351578/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure 5</span></a>). The reduced production of S1P may be associated with decreased
cellular survival and proliferation and increased apoptosis of alveolar cells (<a href="#bib15" rid="bib15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_638654616">15</a>). Much less is known about the significance of
decreased gangliosides (or glycoceramides) in the lung, reports showing association with
diabetes or hearing loss (<a href="#bib27" rid="bib27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751186">27</a>). Although our
earlier genomic analysis hinted at this involvement (<a href="#bib4" rid="bib4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751172">4</a>), this is the first report of decreased monosialodihexosylganglioside
GM3.d18.1.N16.0 as putative biomarker of emphysema. Similarly, the role of
monohexosylceramides in the lung is unknown, but they were shown to bind to surfactant
protein D (<a href="#bib28" rid="bib28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751155">28</a>) and to decrease on activation of
acid sphingomyelinase and acid &#x003b2;-glucosidase1, as a sign of ceramide production
via recycling from gangliosides during inflammation (<a href="#bib29" rid="bib29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751180">29</a>). These results may embolden future investigations of lung sphingolipid
metabolomic signatures and the functional role of the gangliosides and
monohexosylceramides in COPD.</p><p id="__p45">The strongest positive association with COPD exacerbations was for trihexosylceramides
(trihexcer.d18.1.N22.0 and trihexcer.d18.1.N24.0), a lipid class with unknown lung
effects; one case report of Fabry disease (characterized by overabundance of
trihexosylceramides) showed association with COPD (<a href="#bib30" rid="bib30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751153">30</a>). Other sphingolipids such as ceramide (d18.1.N18.0) and S1P were
inversely associated with COPD exacerbations. This, along with negative correlations of
plasma sphingomyelins and ceramides with S1P, suggests a rapid flux of
sphingosine-to-ceramide-to glycosylated ceramides metabolism, with potential disruption
of ceramide-to-S1P metabolism (<a href="/pmc/articles/PMC4351578/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure 5</span></a>) in those
with COPD exacerbations. Alternatively, whether tissues or cells may differentially
contribute to the abundance of plasma metabolites in these individuals could be explored
by comparing plasma with lung tissue metabolomics signatures. Because these samples were
collected at a time remote from an actual exacerbation, metabolomic signatures are
unlikely to reflect corticosteroid or antibiotic treatment or acute infections. Rather,
they may indicate specific changes associated with developing COPD exacerbations. For
example, shunting ceramide metabolism toward trihexosylceramides may render the lungs
more susceptible to inflammation, due to defects in lymphocyte function, as learned from
a mouse model of Fabry disease (<a href="#bib31" rid="bib31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751169">31</a>).</p><p id="__p46">To further translate biomarker findings to disease pathogenesis, we explored alterations
of gene&#x02013;metabolite associations with disease phenotypes. We identified a negative
association of sphingosine levels with the expression of CYR61 only in subjects with
severe COPD. Although the significance of this finding remains to be tested, the
extracellular matrix protein CCN1/Cyr61 is activated by S1P via receptor 2 (<a href="#bib32" rid="bib32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751188">32</a>), which also activates rho kinase to cause lung
damage during cigarette smoke exposure (<a href="#bib33" rid="bib33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751182">33</a>,
<a href="#bib34" rid="bib34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751164">34</a>). Other disrupted gene&#x02013;metabolite
associations of interest in those with severe COPD exacerbations were between ceramide
and alkaline ceramidase, which degrades unsaturated long chain ceramides (<a href="#bib35" rid="bib35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751185">35</a>); ORMDL1, which regulates <em>de
novo</em> ceramide biosynthesis, recently involved in asthma (<a href="#bib36" rid="bib36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751177">36</a>); and 3-ketodihydrosphingosine reductase, which
reduces 3-ketodihydrosphingosine to dihydrosphingosine (<a href="#bib37" rid="bib37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751147">37</a>). Another intriguing association was that between circulating
ceramide and COL4A3BP, also known as CERTL, a gene encoding for ceramide transporter
protein Goodpasture antigen-binding protein, which mediates the nonvesicular
intracellular transport of ceramides (<a href="#bib38" rid="bib38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751149">38</a>).
Superimposing potential sphingolipid biomarkers with genetic signatures helped map the
directionality of sphingolipid metabolism in individuals with COPD exacerbations (<a href="/pmc/articles/PMC4351578/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure 5</span></a>). Using similar approaches may strengthen
the associations of sphingolipid metabolism and chronic bronchitis or obstructive
ventilatory defects in COPD, which were weak at the plasma metabolite levels, but in
conjunction with genomic findings suggested a potential metabolic flux toward higher S1P
and <em>de novo</em> pathway activation, respectively (Figure E3).</p><p id="__p47">In summary, this study demonstrates that specific sphingolipids, such as ceramides,
sphingomyelins, and gangliosides, may be biomarker candidates of COPD phenotypes, such
as emphysema and frequent COPD exacerbations. Our study&#x02019;s strengths include the
large number of highly phenotyped subjects, the multiple specific sphingolipid
measurements, and independent replication. Limitations of our study include lack of
healthy nonsmoking subjects, of longitudinal studies, and of lung tissue,
bronchoalveolar lavage fluid, or sputum analyses. The latter would have allowed us to
probe if plasma findings parallel those in the lung and to validate a small study that
suggested sputum sphingolipids are associated with COPD (<a href="#bib6" rid="bib6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_432751160">6</a>). Our results in a much larger cohort of patients with COPD
corroborate those reported in the sputum, in particular that there are abnormalities in
sphingolipid metabolism and glycosphingolipid changes in COPD. The complementary nature
of these studies conducted in different compartments may help interpret our results in
plasma, which indicate an overall accelerated metabolism/catabolism of ceramide at the
systemic level, in contrast to the increased ceramides and dihydroceramides recovered in
the sputum in COPD. This may be due to active transfer and use of plasma sphingolipids
in the lung with release of ceramides in sputum; alternatively, it may be due to
different dynamics of sphingolipid metabolism in circulating cells and endothelium
compared with airway macrophages or epithelial cells that may contribute to sputum
sphingolipid content.</p><p id="__p48" class="p p-last">Our results strengthen the evidence implicating ceramide in emphysema and suggest a
previously unsuspected role for ceramide metabolism in COPD exacerbations. Furthermore,
our data suggest that additional subclasses of sphingolipids such as sphingomyelins,
gangliosides, monohexosylceramides, and trihexosylceramides should be investigated, to
validate their role as biomarkers and as potential contributors to COPD
pathogenesis.</p></div><div id="idm139927599733632" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139927599733632title">Acknowledgment</h2><div class="sec"><div id="__sec19" class="sec sec-first"><h2></h2><p id="__p49" class="p p-first-last">The authors thank Christina Schnell, Taylor Thorn, and Cori Fratelli for assistance
with recruiting subjects and preparing samples and Kristina Watson for administrative
support.</p></div></div></div><div id="idm139927599732192" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139927599732192title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm139927599732064"><p id="__p50" class="p p-first-last">Funded by National Heart, Lung, and Blood Institute grants U01 HL089856 and U01
HL089897 (Edwin Silverman and James Crapo); National Center for Research
Resources/National Institutes of Health grants UL1 RR025780 and S10 RR023703;
National Institutes of Health/National Center for Advancing Translational Sciences
Colorado Clinical and Translational Science Awards UL1 TR000154 (Ron Sokol), P20
HL-113444 (J.E.S.), and P20 HL-113445 (R.P.B., I.P., and N.R.).</p></p><p class="fn sec" id="idm139927593936848"><p id="__p51" class="p p-first-last">Author Contributions: R.P.B., N.R., and K.K. designed the study; C.C., D.S.O.,
J.E.S., and N.R. generated data; S.J., C.C., G.J.H., C.S., and K.K. analyzed data;
R.P.B., I.P., N.R., and K.K. interpreted data and wrote the manuscript.</p></p><p class="fn sec" id="idm139927593935968"><p id="__p52" class="p p-first-last">Originally Published in Press as DOI: <a href="http://dx.doi.org/10.1164/rccm.201410-1771OC" ref="reftype=extlink&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="_blank">10.1164/rccm.201410-1771OC</a> on December 10, 2014</p></p><p class="fn sec" id="idm139927593934480"><p id="__p53" class="p p-first-last">This article has an online supplement, which is accessible from this issue&#x02019;s
table of contents at <a href="http://www.atsjournals.org" ref="reftype=extlink&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="_blank">www.atsjournals.org</a></p></p><p class="fn sec" id="idm139927594314448"><p id="__p54" class="p p-first-last"><span class="underline"><strong><a href="http://www.atsjournals.org/doi/suppl/10.1164/rccm.201410-1771OC/suppl_file/disclosures.pdf" ref="reftype=extlink&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="_blank">Author disclosures</a></strong></span> are available with the
text of this article at <a href="http://www.atsjournals.org" ref="reftype=extlink&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="_blank">www.atsjournals.org</a>.</p></p></div></div><div id="idm139927594311616" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139927594311616title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="bib1">1.  <span class="element-citation">Murphy SL, Xu J, Kochanek KD. Deaths:
final data for 2010. <span><span class="ref-journal"><em>Natl Vital Stat
Rep</em>. </span>2013;<span class="ref-vol">61</span>:1–117.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/24979972" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib2">2.  <span class="element-citation">Friedlander AL, Lynch D, Dyar LA, Bowler RP. Phenotypes
of chronic obstructive pulmonary
disease. <span><span class="ref-journal"><em>COPD</em>. </span>2007;<span class="ref-vol">4</span>:355–384.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/18027163" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib3">3.  <span class="element-citation">Petrache I, Petrusca DN, Bowler RP, Kamocki K. Involvement
of ceramide in cell death responses in the pulmonary
circulation. <span><span class="ref-journal"><em>Proc Am Thorac
Soc</em>. </span>2011;<span class="ref-vol">8</span>:492–496.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC3359077/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/22052925" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib4">4.  <span class="element-citation">Bahr TM, Hughes GJ, Armstrong M, Reisdorph R, Coldren CD, Edwards MG, Schnell C, Kedl R, LaFlamme DJ, Reisdorph N, et al.  Peripheral blood
mononuclear cell gene expression in chronic obstructive pulmonary
disease. <span><span class="ref-journal"><em>Am J Respir Cell Mol
Biol</em>. </span>2013;<span class="ref-vol">49</span>:316–323.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC3824029/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/23590301" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib5">5.  <span class="element-citation">Ahmed FS, Jiang XC, Schwartz JE, Hoffman EA, Yeboah J, Shea S, Burkart KM, Barr RG. Plasma
sphingomyelin and longitudinal change in percent emphysema on CT. The MESA lung
study. <span><span class="ref-journal"><em>Biomarkers</em>. </span>2014;<span class="ref-vol">19</span>:207–213.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC4088962/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/24649875" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib6">6.  <span class="element-citation">Telenga ED, Hoffmann RF, Ruben t&#x02019;Kindt, Hoonhorst SJ, Willemse BW, van
Oosterhout AJ, Heijink IH, van
den
Berge M, Jorge L, Sandra P, et al.  Untargeted
lipidomic analysis in chronic obstructive pulmonary disease. Uncovering
sphingolipids. <span><span class="ref-journal"><em>Am J Respir Crit Care
Med</em>. </span>2014;<span class="ref-vol">190</span>:155–164.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/24871890" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib7">7.  <span class="element-citation">Hannun YA, Obeid LM. Principles
of bioactive lipid signalling: lessons from
sphingolipids. <span><span class="ref-journal"><em>Nat Rev Mol Cell
Biol</em>. </span>2008;<span class="ref-vol">9</span>:139–150.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/18216770" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib8">8.  <span class="element-citation">Uhlig S, Gulbins E. Sphingolipids
in the lungs. <span><span class="ref-journal"><em>Am J Respir Crit Care
Med</em>. </span>2008;<span class="ref-vol">178</span>:1100–1114.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/18755926" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib9">9.  <span class="element-citation">Yang Y, Uhlig S. The
role of sphingolipids in respiratory
disease. <span><span class="ref-journal"><em>Ther Adv Respir
Dis</em>. </span>2011;<span class="ref-vol">5</span>:325–344.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/21900155" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib10">10.  <span class="element-citation">Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM. Ceramide
upregulation causes pulmonary cell apoptosis and emphysema-like disease in
mice. <span><span class="ref-journal"><em>Nat
Med</em>. </span>2005;<span class="ref-vol">11</span>:491–498.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC1352344/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/15852018" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib11">11.  <span class="element-citation">Scarpa MC, Baraldo S, Marian E, Turato G, Calabrese F, Saetta M, Maestrelli P. Ceramide
expression and cell homeostasis in chronic obstructive pulmonary
disease. <span><span class="ref-journal"><em>Respiration</em>. </span>2013;<span class="ref-vol">85</span>:342–349.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/23018286" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib12">12.  <span class="element-citation">Petrusca DN, Van
Demark M, Gu Y, Justice MJ, Rogozea A, Hubbard WC, Petrache I. Smoking
exposure induces human lung endothelial cell adaptation to apoptotic
stress. <span><span class="ref-journal"><em>Am J Respir Cell Mol
Biol</em>. </span>2014;<span class="ref-vol">50</span>:513–525.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC5455468/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/24079644" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib13">13.  <span class="element-citation">Petrusca DN, Gu Y, Adamowicz JJ, Rush NI, Hubbard WC, Smith PA, Berdyshev EV, Birukov KG, Lee CH, Tuder RM, et al.  Sphingolipid-mediated
inhibition of apoptotic cell clearance by alveolar
macrophages. <span><span class="ref-journal"><em>J Biol
Chem</em>. </span>2010;<span class="ref-vol">285</span>:40322–40332.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC3001012/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/20956540" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib14">14.  <span class="element-citation">Cordts F, Pitson S, Tabeling C, Gibbins I, Moffat DF, Jersmann H, Hodge S, Haberberger RV. Expression
profile of the sphingosine kinase signalling system in the lung of patients with
chronic obstructive pulmonary disease. <span><span class="ref-journal"><em>Life
Sci</em>. </span>2011;<span class="ref-vol">89</span>:806–811.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/21945191" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib15">15.  <span class="element-citation">Diab KJ, Adamowicz JJ, Kamocki K, Rush NI, Garrison J, Gu Y, Schweitzer KS, Skobeleva A, Rajashekhar G, Hubbard WC, et al.  Stimulation of
sphingosine 1-phosphate signaling as an alveolar cell survival strategy in
emphysema. <span><span class="ref-journal"><em>Am J Respir Crit Care
Med</em>. </span>2010;<span class="ref-vol">181</span>:344–352.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC5455841/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/19965812" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib16">16.  <span class="element-citation">Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic
epidemiology of COPD (COPDGene) study
design. <span><span class="ref-journal"><em>COPD</em>. </span>2010;<span class="ref-vol">7</span>:32–43.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC2924193/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/20214461" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib17">17.  <span class="element-citation">Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS GOLD
Scientific Committee. Global strategy for the
diagnosis, management, and prevention of chronic obstructive pulmonary disease:
National Heart, Lung, and Blood Institute and World Health Organization Global
Initiative for Chronic Obstructive Lung Disease (GOLD): executive
summary. <span><span class="ref-journal"><em>Respir
Care</em>. </span>2001;<span class="ref-vol">46</span>:798–825.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/11463370" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib18">18.  <span class="element-citation">Carolan BJ, Kim YI, Williams AA, Kechris K, Lutz S, Reisdorph N, Bowler RP. The
association of adiponectin with computed tomography phenotypes in chronic
obstructive pulmonary disease. <span><span class="ref-journal"><em>Am J Respir
Crit Care
Med</em>. </span>2013;<span class="ref-vol">188</span>:561–566.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC3827701/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/23777323" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib19">19.  <span class="element-citation">Yang Y, Cruickshank C, Armstrong M, Mahaffey S, Reisdorph R, Reisdorph N. New
sample preparation approach for mass spectrometry-based profiling of plasma
results in improved coverage of
metabolome. <span><span class="ref-journal"><em>J Chromatogr
A</em>. </span>2013;<span class="ref-vol">1300</span>:217–226.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC3734953/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/23672979" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib20">20.  <span class="element-citation">Stouffer SA.  Princeton: Princeton
University
Press; 1949. The
American
soldier.</span></div><div class="ref-cit-blk half_rhythm" id="bib21">21.  <span class="element-citation">Liptak T. On
the combination of independent
tests. <span><span class="ref-journal"><em>Magyar Tudomanyos Akademia
Matematikai Kutato Intezetenek
Kozlemenyei</em>. </span>1958;<span class="ref-vol">3</span>:171–179.</span></span></div><div class="ref-cit-blk half_rhythm" id="bib22">22.  <span class="element-citation">Taniguchi M, Okazaki T. The
role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and
migration-from cell and animal models to human
disorders. <span><span class="ref-journal"><em>Biochim Biophys
Acta</em>. </span>2014;<span class="ref-vol">1841</span>:692–703.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/24355909" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib23">23.  <span class="element-citation">Hojjati MR, Jiang XC. Rapid,
specific, and sensitive measurements of plasma sphingomyelin and
phosphatidylcholine. <span><span class="ref-journal"><em>J Lipid
Res</em>. </span>2006;<span class="ref-vol">47</span>:673–676.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/16371647" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib24">24.  <span class="element-citation">Levy M, Khan E, Careaga M, Goldkorn T. Neutral
sphingomyelinase 2 is activated by cigarette smoke to augment ceramide-induced
apoptosis in lung cell death. <span><span class="ref-journal"><em>Am J Physiol
Lung Cell Mol
Physiol</em>. </span>2009;<span class="ref-vol">297</span>:L125–L133.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC2711801/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/19395669" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib25">25.  <span class="element-citation">Medler TR, Petrusca DN, Lee PJ, Hubbard WC, Berdyshev EV, Skirball J, Kamocki K, Schuchman E, Tuder RM, Petrache I. Apoptotic
sphingolipid signaling by ceramides in lung endothelial
cells. <span><span class="ref-journal"><em>Am J Respir Cell Mol
Biol</em>. </span>2008;<span class="ref-vol">38</span>:639–646.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC2396244/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/18192502" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib26">26.  <span class="mixed-citation">Petrache I, Petrusca DN. <span class="ref-title">The
involvement of sphingolipids in chronic obstructive pulmonary
diseases</span>In: Gulbins E, Petrache I, editors. editorsSphingolipids
in disease. Handbook of experimental pharmacologyVol.
216Heidelberg,
Germany: Springer-Verlag
GmbH; 2013. pp.
247&#x02013;264  <span class="nowrap ref pubmed">[<a href="/pubmed/23563660" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib27">27.  <span class="element-citation">Inokuchi J. Physiopathological
function of hematoside (GM3
ganglioside) <span><span class="ref-journal"><em>Proc Jpn Acad, Ser B, Phys
Biol
Sci</em>. </span>2011;<span class="ref-vol">87</span>:179–198.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC3149380/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/21558756" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib28">28.  <span class="element-citation">Kuroki Y, Gasa S, Ogasawara Y, Shiratori M, Makita A, Akino T. Binding
specificity of lung surfactant protein SP-D for
glucosylceramide. <span><span class="ref-journal"><em>Biochem Biophys Res
Commun</em>. </span>1992;<span class="ref-vol">187</span>:963–969.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/1530650" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib29">29.  <span class="element-citation">Kitatani K, Sheldon K, Rajagopalan V, Anelli V, Jenkins RW, Sun Y, Grabowski GA, Obeid LM, Hannun YA. Involvement
of acid beta-glucosidase 1 in the salvage pathway of ceramide
formation. <span><span class="ref-journal"><em>J Biol
Chem</em>. </span>2009;<span class="ref-vol">284</span>:12972–12978.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC2676029/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/19279011" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib30">30.  <span class="element-citation">Wang RY, Abe JT, Cohen AH, Wilcox WR. Enzyme
replacement therapy stabilizes obstructive pulmonary Fabry disease associated with
respiratory globotriaosylceramide
storage. <span><span class="ref-journal"><em>J Inherit Metab
Dis</em>. </span>2008;<span class="ref-vol">31</span>:S369–S374.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/18937048" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib31">31.  <span class="element-citation">Pereira CS, Azevedo O, Maia ML, Dias AF, Sa-Miranda C, Macedo MF. Invariant
natural killer T cells are phenotypically and functionally altered in Fabry
disease. <span><span class="ref-journal"><em>Mol Genet
Metab</em>. </span>2013;<span class="ref-vol">108</span>:241–248.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/23433711" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib32">32.  <span class="element-citation">Young N, Van
Brocklyn JR. Roles
of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells.
Differential effects of S1P2 on cell migration and
invasiveness. <span><span class="ref-journal"><em>Exp Cell
Res</em>. </span>2007;<span class="ref-vol">313</span>:1615–1627.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC2100382/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/17376432" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib33">33.  <span class="element-citation">Richens TR, Linderman DJ, Horstmann SA, Lambert C, Xiao YQ, Keith RL, Bo&#x000e9; DM, Morimoto K, Bowler RP, Day BJ, et al.  Cigarette smoke
impairs clearance of apoptotic cells through oxidant-dependent activation of
RhoA. <span><span class="ref-journal"><em>Am J Respir Crit Care
Med</em>. </span>2009;<span class="ref-vol">179</span>:1011–1021.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC2689911/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/19264974" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib34">34.  <span class="element-citation">Schweitzer KS, Hatoum H, Brown MB, Gupta M, Justice MJ, Beteck B, Van
Demark M, Gu Y, Presson RG, Jr, Hubbard WC, et al.  Mechanisms of lung
endothelial barrier disruption induced by cigarette smoke: role of oxidative
stress and ceramides. <span><span class="ref-journal"><em>Am J Physiol Lung
Cell Mol
Physiol</em>. </span>2011;<span class="ref-vol">301</span>:L836–L846.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC3233827/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/21873444" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib35">35.  <span class="element-citation">Hu W, Xu R, Sun W, Szulc ZM, Bielawski J, Obeid LM, Mao C. Alkaline
ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides, and its
down-regulation inhibits both cell proliferation and
apoptosis. <span><span class="ref-journal"><em>J Biol
Chem</em>. </span>2010;<span class="ref-vol">285</span>:7964–7976.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC2832947/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/20068046" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib36">36.  <span class="element-citation">Michel S, Busato F, Genuneit J, Pekkanen J, Dalphin JC, Riedler J, Mazaleyrat N, Weber J, Karvonen AM, Hirvonen MR, et al.  PASTURE study
group. Farm exposure and time trends in early
childhood may influence DNA methylation in genes related to asthma and
allergy. <span><span class="ref-journal"><em>Allergy</em>. </span>2013;<span class="ref-vol">68</span>:355–364.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/23346934" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib37">37.  <span class="element-citation">Kihara A, Igarashi Y. FVT-1
is a mammalian 3-ketodihydrosphingosine reductase with an active site that faces
the cytosolic side of the endoplasmic reticulum
membrane. <span><span class="ref-journal"><em>J Biol
Chem</em>. </span>2004;<span class="ref-vol">279</span>:49243–49250.</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/15328338" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib38">38.  <span class="element-citation">Kudo N, Kumagai K, Tomishige N, Yamaji T, Wakatsuki S, Nishijima M, Hanada K, Kato R. Structural
basis for specific lipid recognition by CERT responsible for nonvesicular
trafficking of ceramide. <span><span class="ref-journal"><em>Proc Natl Acad Sci
USA</em>. </span>2008;<span class="ref-vol">105</span>:488–493.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="/pmc/articles/PMC2206563/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="/pubmed/18184806" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4351578&amp;issue-id=250240&amp;journal-id=465&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">American Journal of Respiratory and Critical Care Medicine</span> are provided here courtesy of <strong>American Thoracic Society</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC4351578/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC4351578/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC4351578/pdf/rccm.201410-1771OC.pdf">PDF (840K)</a></li> | <li><a href="#" data-citationid="PMC4351578" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4351578%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4351578%2F&amp;text=Plasma%20Sphingolipids%20Associated%20with%20Chronic%20Obstructive%20Pulmonary%0ADisease%20Phenotypes"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4351578%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="25494452" data-aiid="4351578" data-aid="4351578" data-iid="250240" data-domainid="465" data-domain="ajrccm" data-accid="PMC4351578" data-md5="13ae310201c5ee4fc0c455c9563884e8"></div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2018-07-16T19:05:43-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc201&amp;ncbi_phid=F4FB7B1CB4D247E100000000002D0020&amp;ncbi_session=F4FB7B1CB4D24C71_0045SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4351578%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=ajrccm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC4351578/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FB7B1CB4D24C71_0045SID /projects/PMC/PMCViewer@4.46 ptpmc201 v4.1.r563004 Tue, May 01 2018 03:01:28 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>
</html>